Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Qu, Yiqing ^a   Wu, Xiuxiu ^a   Yin, Yunhong ^a   Yang, Yan ^a   Ma, Dedong ^a   Li, Hao ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AZD6244; BEZ235; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SELUMETINIB; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CANCER TISSUE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL TISSUE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR CELL;

ANIMALS; ANTIGENS, CD31; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; KI-67 ANTIGEN; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES; QUINOLINES; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902301768     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-52     Document Type: Article

References (38)

1. Lung cancer in China: challenges and interventions. She J, Yang P, Hong Q, Bai C, Chest 2013 143 1117 1126
2. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK, J Natl Cancer Inst 2003 95 1276 1299 (Pubitemid 37160862)
3. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu JM, Johnson DH, N Engl J Med 2002 346 92 98 (Pubitemid 34438899)
4. Rational, biologically based treatment of EGFR mutant non-small-cell lung cancer. Pao W, Chmielecki J, Nat Rev Cancer 2010 10 760 774
5. Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W, Proc Natl Acad Sci U S A 2007 104 20932 20937
6. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA, Science 2007 316 1039 1043 (Pubitemid 46799492)
7. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA, Sci Transl Med 2011 3 75ra26
8. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, PLoS Med 2005 2 17
9. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Huynh H, Soo KC, Chow PK, Tran E, Mol Cancer Ther 2007 6 138 146 (Pubitemid 46206676)
10. Biological characterisation of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E, Clin Cancer Res 2007 13 1576 1583 (Pubitemid 46450450)
11. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Huynh H, Chow PK, Soo KC, Mol Cancer Ther 2007 6 2468 2476 (Pubitemid 47480412)
12. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK, Proc Natl Acad Sci U S A 2009 106 18351 18356
13. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR, Clin Cancer Res 2009 15 4649 4664
14. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García- Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK, Nat Med 2008 14 1351 1356
15. Targeting the phosphoinositide 3-kinase pathway in cancer. Liu P, Cheng H, Roberts TM, Zhao JJ, Nat Rev Drug Discov 2009 8 627 644
16. Anti-tumor effect of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, Hollander I, Clin Cancer Res 2011 17 3193 3203
17. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD, Mol Cancer Ther 2011 10 336 346
18. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J, J Thorac Oncol 2012 7 1211 1217
19. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellularsignal-regulated kinase kinase 1/2 kinases: mechanism ofaction in vivo, pharmacokinetic/pharmacodynamicmodels relationship, and potential for combination in preclinical. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD, Mol Cancer Ther 2007 6 2209 2219 (Pubitemid 47294749)
20. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Matsumoto K, Yano S, Int J Cancer 2013 133 505 514
21. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Chou TC, Talalay P, Adv Enzyme Regul 1984 22 27 55
22. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Mitsudomi T, Yatabe Y, Cancer Sci 2007 98 1817 1824 (Pubitemid 350002184)
23. Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Friday BB, Adjei AA, Clin Cancer Res 2008 14 342 346 (Pubitemid 351226098)
24. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Robinson KW, Sandler AB, Oncologist 2013 18 115 122
25. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W, J Clin Invest 2009 119 3000 3010
26. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Fremin C, Meloche S, J Hematol Oncol 2010 3 8 14
27. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG, J Clin Oncol 2008 26 2139 2146
28. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA, Oncotarget 2014 5 1502 1514
29. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F, Cancer Res 2009 69 4286 4293
30. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A, Clin Cancer Res 2012 18 2316 2325
31. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H, PLoS Med 2005 2 73
32. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK, Oncogene 2008 27 4702 4711
33. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA, Clin Cancer Res 2009 15 2552 2558
34. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M, Lung Cancer 2011 73 361 365
35. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ, Mol Cancer Ther 2010 9 1985 1994
36. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF, Cancer Res 1991 51 4999 5002
37. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF, Oncogene 1991 6 1353 1362 (Pubitemid 21924231)
38. Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. Murray S, Karavasilis V, Bobos M, Razis E, Papadopoulos S, Christodoulou C, Kosmidis P, Fountzilas G, J Exp Clin Cancer Res 2012 31 77